Japan Tissue Engineering Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2022
April 26, 2022 at 02:30 am EDT
Share
Japan Tissue Engineering Co., Ltd. reported earnings results for the full year ended March 31, 2022. For the full year, the company reported sales was JPY 391.21 million compared to JPY 721.63 million a year ago. Revenue was JPY 2,103.44 million compared to JPY 2,257.61 million a year ago. Net loss was JPY 497.89 million compared to JPY 466.62 million a year ago. Basic loss per share from continuing operations was JPY 12.26 compared to JPY 11.49 a year ago.
Japan Tissue Engineering Co Ltd is a Japan-based company mainly engaged in regenerative medicine product business, regenerative medicine outsourcing business, and research and development support business. The Company operates through three segments. The Regenerative Medicine Product segment develops regenerative medicine products using tissue engineering, and manufactures and sells the products for medical institutions. The regenerative medicine products include autologous cultured epidermis JACE, and autologous cultured cartilage JACK. The Regenerative Medicine Outsourcing segment provides contract development and manufacturing organization (CDMO) services, contract research organization (CRO) services, consulting services, and contract manufacturing services for specific cell processed products. The Research and Development Support segment manufactures and sells human cultured tissues that apply advanced culture technology accumulated through the development of in-house products.
JAPAN TISSUE ENGINEERING CO., LTD. 
